171 related articles for article (PubMed ID: 25616354)
1. Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells.
Shimoyama K; Kagawa S; Ishida M; Watanabe S; Noma K; Takehara K; Tazawa H; Hashimoto Y; Tanabe S; Matsuoka J; Kobayashi H; Fujiwara T
Breast Cancer Res Treat; 2015 Feb; 149(3):597-605. PubMed ID: 25616354
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer.
Ishida M; Kagawa S; Shimoyama K; Takehara K; Noma K; Tanabe S; Shirakawa Y; Tazawa H; Kobayashi H; Fujiwara T
Mol Cancer Ther; 2016 Mar; 15(3):402-11. PubMed ID: 26832799
[TBL] [Abstract][Full Text] [Related]
3. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging.
Ito K; Mitsunaga M; Nishimura T; Kobayashi H; Tajiri H
Oncotarget; 2016 Mar; 7(12):14143-52. PubMed ID: 26909859
[TBL] [Abstract][Full Text] [Related]
4. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer.
Yamashita S; Kojima M; Onda N; Yoshida T; Shibutani M
Cancer Med; 2023 Feb; 12(4):4579-4589. PubMed ID: 36259134
[TBL] [Abstract][Full Text] [Related]
6. Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms.
Ito K; Mitsunaga M; Arihiro S; Saruta M; Matsuoka M; Kobayashi H; Tajiri H
BMC Cancer; 2016 Jan; 16():37. PubMed ID: 26810644
[TBL] [Abstract][Full Text] [Related]
7. Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer.
Yamaguchi H; On J; Morita T; Suzuki T; Okada Y; Ono J; Evdokiou A
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830099
[TBL] [Abstract][Full Text] [Related]
8. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
Ghedini GC; Ciravolo V; Tortoreto M; Giuffrè S; Bianchi F; Campiglio M; Mortarino M; Figini M; Coliva A; Carcangiu ML; Zambetti M; Piazza T; Ferrini S; Ménard S; Tagliabue E; Pupa SM
J Cell Physiol; 2010 Oct; 225(1):256-65. PubMed ID: 20506359
[TBL] [Abstract][Full Text] [Related]
9. Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT).
Siddiqui MR; Railkar R; Sanford T; Crooks DR; Eckhaus MA; Haines D; Choyke PL; Kobayashi H; Agarwal PK
Sci Rep; 2019 Feb; 9(1):2084. PubMed ID: 30765854
[TBL] [Abstract][Full Text] [Related]
10. Near infrared photoimmunotherapy for lung metastases.
Sato K; Nagaya T; Mitsunaga M; Choyke PL; Kobayashi H
Cancer Lett; 2015 Aug; 365(1):112-21. PubMed ID: 26021765
[TBL] [Abstract][Full Text] [Related]
11. Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT.
Nishimura T; Mitsunaga M; Ito K; Kobayashi H; Saruta M
Gastric Cancer; 2020 Jan; 23(1):82-94. PubMed ID: 31302791
[TBL] [Abstract][Full Text] [Related]
12. Near-Infrared Photoimmunotherapy Using a Small Protein Mimetic for HER2-Overexpressing Breast Cancer.
Yamaguchi H; Pantarat N; Suzuki T; Evdokiou A
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757056
[TBL] [Abstract][Full Text] [Related]
13. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
Lennon S; Barton C; Banken L; Gianni L; Marty M; Baselga J; Leyland-Jones B
J Clin Oncol; 2009 Apr; 27(10):1685-93. PubMed ID: 19255335
[TBL] [Abstract][Full Text] [Related]
14. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
[TBL] [Abstract][Full Text] [Related]
18. Near infrared photoimmunotherapy prevents lung cancer metastases in a murine model.
Sato K; Nagaya T; Nakamura Y; Harada T; Choyke PL; Kobayashi H
Oncotarget; 2015 Aug; 6(23):19747-58. PubMed ID: 25992770
[TBL] [Abstract][Full Text] [Related]
19. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
Savellano MD; Pogue BW; Hoopes PJ; Vitetta ES; Paulsen KD
Cancer Res; 2005 Jul; 65(14):6371-9. PubMed ID: 16024640
[TBL] [Abstract][Full Text] [Related]
20. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
